Vanessa Lucey is the Associate Director of the Anna Maria-Kellen Clinical Accelerator and Venture Fund at the Cancer Research Institute (CRI’s), New York, NY. The Anna-Maria Kellen Clinical Accelerator, the clinical arm of CRI, is a unique academia-nonprofit-industry collaboration model that serves as an “incubator” to accelerate clinical trials of promising new immunotherapy combinations. At CRI, Vanessa developed CRI’s first-of-its-kind the global immuno-oncology (IO) database to track the landscape from discovery to clinic that was recently published in the Annals of Oncology.
Vanessa has over 15 years’ experience in tumor immunology; she received her Ph.D. from Albert Einstein College of Medicine, her postdoctoral fellowship at NYU School of Medicine, where she has authored or co-authored 27 publications. Vanessa also received her M.B.A from Mercy College School of Business.